The European Patent Office (EPO) has granted patent EP3504318B1, which details a method for improving methyltransferase activity. This grant is a final decision on the patent application, establishing intellectual property rights for the inventors in the designated European states.

This patent grant does not impose new regulatory obligations on companies. However, it may affect companies operating in the biotechnology and pharmaceutical sectors by potentially impacting their freedom to operate or their competitive landscape concerning methyltransferase-related technologies. Companies should be aware of this granted patent and its implications for their research and development activities.